Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Fabrinet (FN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Fabrinet — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while Fabrinet trades at $544 (market cap $18.88B). The key difference: Fabrinet is far larger — about 3.7× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Fabrinet nearer its low. Which is the better fit depends on your goals.
| ACAD | FN | |
|---|---|---|
Market Cap | $5.06B | $18.88B |
Sector | Health | Technology |
52-Week High | $29.41 | $746.47 |
52-Week Low | $20.06 | $277.04 |
Enterprise Value | $4.18B | $17.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Fabrinet (FN) trades at $562.38, up 3.39% in 24 hours, near its 52-week high of $748.89. The stock shows bullish technical signals with strong moving average support and a neutral RSI. Recent earnings beats in Q3 2025 to Q1 2026 highlight robust growth, with Q2 2026 EPS expected at $3.81. Revenue grew to $3.42B in 2025, with net income at $332.53M, though valuation ratios like P/E of 45.28 appear elevated.
Outlook remains positive driven by AI infrastructure demand, with analysts projecting 75% buy ratings. Key risks include premium valuation sensitivity and supply chain constraints. The stock offers growth exposure but requires monitoring of execution and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →
